AT 1015

Drug Profile

AT 1015

Latest Information Update: 05 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajinomoto
  • Class Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic neuropathies; Intermittent claudication; Thrombosis

Most Recent Events

  • 05 Sep 2002 Discontinued - Phase-I for Diabetic neuropathies in Japan (unspecified route)
  • 05 Sep 2002 Discontinued - Phase-I for Thrombosis in Japan (unspecified route)
  • 05 Sep 2002 Discontinued - Phase-II for Intermittent claudication in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top